This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.
Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study
by Zacks Equity Research
Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
by Zacks Equity Research
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
Pfizer's Breast Cancer Drug Misses Overall Survival in Study
by Zacks Equity Research
Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.
Roche's (RHHBY) Study on Tecentriq for Lung Cancer Positive
by Zacks Equity Research
Roche's (RHHBY) phase III study on immuno-oncology drug, Tecentriq, for the treatment of small cell lung cancer meet its co-primary endpoints.
Incyte (INCY) Announces Positive Results on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
by Zacks Equity Research
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
Teva to Discontinue a Fremanezumab Study on Cluster Headache
by Zacks Equity Research
Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.
Novartis Announces Positive Data on CAR-T Therapy, Kymriah
by Zacks Equity Research
Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.
Large Cap Pharma Stock Outlook: Short-Term Struggle Likely
by Zacks Equity Research
Drug pricing scrutiny, pricing and competitive pressure, and major pipeline setbacks can hurt the performance of the large-cap pharmaceuticals sector in the short term.
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.
Mylan (MYL) to Get CRL Again for Generic Advair from FDA
by Zacks Equity Research
Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
by Zacks Equity Research
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Galmed (GLMD) Soars on Positive NASH Data on Aramchol
by Zacks Equity Research
Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.
Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
by Zacks Equity Research
Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.
Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica
by Zacks Equity Research
Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.
ASCO Ends: Winners & Losers at the Key Cancer Research Event
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Novartis Announces Positive Data on Kisqali and Tasigna
by Zacks Equity Research
Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO.
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
by Indrajit Bandyopadhyay
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.
Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
by Zacks Equity Research
Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.
Roche's Tecentriq Study Meets Co-Primary Endpoints for NSCLC
by Zacks Equity Research
Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer.
Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why
by Zacks Equity Research
Teva's (TEVA) shares gain 17% in 2018 so far after declining sharply in 2017.
Eisai and Merck Announce Update on Lenvatinib sNDA Review
by Zacks Equity Research
Eisai/Merck's (MRK) sNDA for cancer drug, lenvatinib, seeking approval for first-line treatment of HCC gets a three-month extension from the FDA.
FDA Confirms September Action Date for Teva's Migraine Drug
by Zacks Equity Research
Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.